animal studies suggest it may support healing of gastric ulcers and damaged intestinal lining Preclinical models suggest it may help modulate inflammation, though this has not been established in controlled human trials Known risks and side effects: Because it is sold as an unregulated research chemical rather than a manufactured pharmaceutical, product purity and dosing accuracy cannot be verified, and the FDA has flagged potential impurities and manufacturing-quality concerns FDA's Category 2 determination specifically cited potential immune reactions and hypersensitivity as a safety concern User-reported (non-clinical-trial) effects include injection-site irritation, redness, or swelling, along with occasional headache, nausea, or lightheadedness, based on anecdotal reporting rather than controlled studies No long-term human safety data exists

Dihydrolipoic Acid is an excellent antioxidant, and that is very important because O 2 ?- is a relatively mild oxidant that is therefore much more selective and can be useful to discriminate between the antioxidant capacities of different substrates [1]
These studies established MT-II as the most pharmacologically validated centrally acting pro-erectile melanocortin agonist in pre-clinical research and provided the foundational data that led to the development of PT-141 as a more selective pro-sexual research compound
Patients often report: More energy and improved mood Better sleep Reduced need for medications like insulin or blood pressure meds Less joint pain and inflammation A sense of empowerment and confidence Because we treat weight as a medical issuenot a personal failure our patients feel supported, not judged